Home / Intelligence / Webinars / Elevating Commercialization in China Part 1: The Path to Launch
Available On Demand
The pharmaceutical market in China has experienced tremendous growth over the past several decades and is becoming increasingly important. While many life sciences organizations consider China to be a ‘must win’ market, commercial success can be elusive. Despite the large patient base and recent economic and political tailwinds driving the advancement of the healthcare industry, sales for innovative drugs in China are often only a fraction of those in the U.S. The complex and rapidly evolving market dynamics require companies to stay on the cutting edge of new regulatory pathways, pricing/market access and go-to-market models.
Join Trinity Life Sciences’ APAC experts as they explore the key dynamics of the pharmaceutical market in China and uncover multiple strategies and levers that can elevate commercial success in this market.
In this three-part webinar series, our experts will explore:
Part 1: The Path to Launch | Available On Demand
Leveraging novel commercialization pathways for innovative therapies
Part 2: The Key to Pricing & Access Optimization | October 18th or 19th
Decoding the current dynamics and future trends of Pricing and Market Access
Part 3: The Winning Commercial Model | Upcoming
Building a model to match China’s changing dynamics
Key Topics Covered In Part 1:
- Regulatory pathways to accelerate commercial launch in China
- Balancing pros and cons
- Insights from recent launches
Featuring
Andy Wong
Partner,
Strategic Advisory
Tony Xu
Associate Principal,
Strategic Advisory
Yitong Li
Senior Consultant & APAC Expert,
Strategic Advisory
Complete the form below to view the on-demand webinar:
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Related Intelligence
Blog
NRDL 2024: Rare Diseases Deep Dive
China’s pharmaceutical landscape is not only vast in scale but also rapidly evolving with an emphasis on balancing access with affordability. This year’s NRDL update stands out. The introduction of the value rating system continues to raise the bar for clinical innovation, rewarding innovation that truly addresses unmet needs and demonstrates clear differentiation. The National […]
Read More
Blog
Joint Clinical Assessment in the EU: What Life Sciences Companies Need to Know
March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences, stakeholders gathered to explore the implications of this new regulatory framework and how to […]
Read More
Blog
Pricing and Access in Germany: Innovation and Strong Evidence Rewarded
Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated drug pricing, incentives for local clinical trials, simplified clinical trial approvals and harmonization of […]
Read More